A. A. Secord, M. Bookman, R. E. Coleman, Minh H. Dinh, N. Khandelwal, K. Benjamin, Rajesh Kamalakar, Danielle Sullivan, David Cella
{"title":"在新诊断的卵巢癌患者中,veliparib +卡铂/紫杉醇(CP) vs单独使用CP的质量调整(QA)无进展生存分析","authors":"A. A. Secord, M. Bookman, R. E. Coleman, Minh H. Dinh, N. Khandelwal, K. Benjamin, Rajesh Kamalakar, Danielle Sullivan, David Cella","doi":"10.1136/ijgc-2020-igcs.16","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":254448,"journal":{"name":"Oral Plenary","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer\",\"authors\":\"A. A. Secord, M. Bookman, R. E. Coleman, Minh H. Dinh, N. Khandelwal, K. Benjamin, Rajesh Kamalakar, Danielle Sullivan, David Cella\",\"doi\":\"10.1136/ijgc-2020-igcs.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":254448,\"journal\":{\"name\":\"Oral Plenary\",\"volume\":\"17 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Plenary\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2020-igcs.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Plenary","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2020-igcs.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer